Kestra Medical Technologies, Ltd. (KMTS)
| Market Cap | 1.26B |
| Revenue (ttm) | 83.72M |
| Net Income (ttm) | -148.12M |
| Shares Out | 58.37M |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 241,294 |
| Open | 22.24 |
| Previous Close | 22.23 |
| Day's Range | 21.46 - 23.25 |
| 52-Week Range | 13.25 - 30.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 26.75 (+23.5%) |
| Earnings Date | Mar 17, 2026 |
About KMTS
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company’s develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardiovert... [Read more]
Financial Performance
In fiscal year 2025, KMTS's revenue was $59.82 million, an increase of 115.05% compared to the previous year's $27.81 million. Losses were -$126.14 million, 25.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for KMTS stock is "Buy." The 12-month stock price target is $26.75, which is an increase of 23.50% from the latest price.
News
Kestra Showcases Accelerated Innovation at HRS 2026
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
KIRKLAND, Wash., April 09, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
KIRKLAND, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it has been name...
Kestra Medical Technologies Earnings Call Transcript: Q3 2026
Q3 revenue grew 63% year-over-year to $24.6M, with gross margin up to 52.6% and strong prescription growth. Fiscal 2026 revenue guidance was raised to $93M, and recent payer wins in Florida and the VA are expected to drive further growth and margin expansion.
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results...
Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will rep...
Kestra Medical Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Kestra is rapidly expanding in an underserved $10B U.S. market, driven by strong clinical results, high patient compliance, and a scalable rental model. Recent innovations, including a partnership with Biobeat for blood pressure monitoring, and robust insurance coverage support continued double-digit growth.
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annua...
Kestra Medical Technologies Earnings Call Transcript: Q2 2026
Q2 FY26 saw 53% revenue growth and gross margin surpassing 50% for the first time, driven by strong prescription volume, market expansion, and improved in-network mix. Updated guidance raises FY26 revenue to $91M, with continued investments in commercial expansion and clinical evidence supporting further growth.
Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the ...
Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares
KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public of...
Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial resu...
Kestra Medical Technologies Transcript: Stifel 2025 Healthcare Conference
A landmark post-approval study has strengthened clinical and competitive positioning, with new data expected to drive market share gains and potentially influence clinical guidelines. Operational execution remains strong, with scalable sales expansion and ongoing innovation supporting future growth.
Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra's ASSURE Device
KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from the ...
Kestra Medical Technologies to Present Late-Breaking ACE-PAS Trial Results at AHA 2025, Showcasing Next-Generation Wearable Defibrillator System
KIRKLAND, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies to Present at the Stifel 2025 Healthcare Conference
KIRKLAND, Wash., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management
KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 He...
Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors
KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Eliza...
Kestra Medical Technologies Earnings Call Transcript: Q1 2026
Revenue grew 52% year over year to $19.4 million, with gross margin expanding to 45.7% and prescription volume up 51%. Fiscal 2026 revenue guidance was raised to $88 million, reflecting strong commercial execution and ongoing market share gains. Clinical milestones and improved payer mix support continued growth.
Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.